The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...

- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby contains the active ingredient ...

Attruby’s (acoramidis) dosage for transthyretin amyloid cardiomyopathy is typically two tablets twice per day. Your dosing schedule may vary based on factors such as your symptoms and other ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

Attruby (acoramidis) can cause certain side effects, including diarrhea and pain in the upper abdomen. Serious side effects haven’t been reported with Attruby. If you experience side effects that are ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los ...

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also ...

BridgeBio Pharma's Attruby shows strong potential in treating ATTR-CM, with a 42% reduction in mortality, competitive pricing, and convenient pill form. Early commercial launch success, high ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...